Targets › POLR1C
1 program from 1 company in 9 trials: 3 Phase 4, 2 Phase 3, 2 Phase 2, 2 Phase 1; Neurology, Infectious disease, Psychiatry; next expected readout Jan 2028.
DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Common component of RNA polymerases I and III which synthesize ribosomal RNA precursors and short non-coding RNAs including 5S rRNA, snRNAs, tRNAs and miRNAs, respectively. (UniProt, O15160)
Open in Phaseline: the race on POLR1C, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gilead Sciences | Emtricitabine Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLR2A, POLR1C | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection; Hiv; Alcohol Use, Unspecified; Pre-exposure Prophylaxis … | Jan 2028 |
Pre-Exposure Prophylaxis of HIV Infection (2) Hiv (1) Alcohol Use, Unspecified (1) Pre-exposure Prophylaxis (1) HIV/AIDS (1) Long Covid (1) Mild Cognitive Impairment (MCI) (1) Healthy Volunteer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.